Loading

Clinical Research in Infectious Diseases

Gender Bias in Human Papillomavirus-Associated Anal and Oral Cancers

Short Communication | Open Access Volume 3 | Issue 1 |

  • 1. The Jake Gittlen Laboratories for Cancer Research, Pennsylvania State University College of Medicine, USA
  • 2. Department of Pathology, Pennsylvania State University College of Medicine, USA
  • 3. Department of Comparative Medicine, Pennsylvania State University College of Medicine, USA
+ Show More - Show Less
Corresponding Authors
Xuwen Peng, Department of Comparative Medicine, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Abstract

HPV-associated anal and oral cancers are increasing. The reason is still unclear although sexual behavior changes in the general population are postulated as one of the factors. The incidence is drastically higher in specific risk groups, such as men who have sex with men, and HIV-1 infected individuals. Interestingly, anal cancer is predominant in women while a higher incidence of oral cancer is found in men. This review gives a brief summary of epidemic, risk factors, mechanisms, diagnosis, and treatment of these two HPV-associated cancers.  

Citation

Hu J, Peng X (2016) Gender Bias in Human Papillomavirus-Associated Anal and Oral Cancers. Clin Res Infect Dis 3(1): 1025

ABBREVIATIONS

HPV: Human Papillomavirus; MSM: Men who have Sex with Men; AIN: Anal Intraepithelial Neoplasia; OSCC: Oropharyngeal Squamous Cell Carcinomas

INTRODUCTION

Most sexually active individuals will have detectable human papillomavirus (HPV) at least once in their lifetime. Fourteen million people are infected annually, and 79 million people have the prevalent infection. Approximate 5% of the cancers globally are HPV-associated anogenital or oral cancers [1]. HPV is transmitted frequently between partners; more frequent transmission has been reported from females to males than from males to females [2]. The incidence of anal and oral cancers related to HPV is increasing in the general population and is growing even faster among individuals who are immunocompromised because of human immunodeficiency virus [HIV] infection [3,4]. Two prophylactic vaccines (Gardasil and Cervarix) have been approved for a decade. Recently, the nonavalent vaccine including additional high-risk HPV types is promised to provide more coverage against cervical cancers[5]. The HPV vaccine is recommended routinely for 11- or 12-year-olds, as well as for young men through age 21 years and young women through age 26 years who have not previously been vaccinated. HPV vaccine is also recommended for men who have sex with men (MSM), people living with HIV/AIDS, and immunocompromised persons through age 26 years. However, the high-risk HPV types included in the nonavalent vaccine contribute little to anal, oropharyngeal, penile, vulvar and vaginal cancer [5,6].

HPV infection is mostly asymptomatic, but may also have many diverse clinical signs encompassing benign anogenital lesions, and carcinomas [6]. Recently, anal and oral cancers are becoming the focus because the incidence has been greatly increasing in developed countries over the last decades, both in women and men, and the incidence is drastically higher in specific risk groups, such as MSM, and HIV-1 infected individuals [7,8]. A higher incidence of anal cancer as compared to oral cancer has been reported in HIV-infected individuals, which suggests that the anal epithelium may be more susceptible to HPV infection [10]. In this short review, the gender bias of these two HPV-associated cancers in the general population will be discussed.

HPV-ASSOCIATED ANAL CANCER

The HPV-associated anal cancer is a rare malignancy of the distal gastrointestinal tract. Ninety to ninety three percent of anal canal cancers are the clinical manifestation of HPV infection [1]. The incidence of HPV-related anal squamous cell carcinoma is increasing [9]. In general, anal HPV is more common in women as in men, and significantly more women than men carry multiple HPV types [9-12]. However, both MSM and heterosexual men showed a remarkable prevalence of anal HPV infection [7]. HIV-infected MSM and heterosexual HIV-infected men were also at risk for acquiring and sustaining persistent high-risk HPV types at the anal and penile sites and are also at risk for developing dysplasia at these sites in the future [18]. Unlike women, prevalence rates in men are steady at all ages, suggesting that men do not develop effective protection against reinfection [5]. Anal intraepithelial neoplasia (AIN) are very common throughout a wide range of ages in both HIV-negative and HIV-positive MSM [6]. The few studies on the natural history of AIN in HIV-infected men suggest that high-grade AIN is a precursor to invasive anal cancer. The incidence of anal cancer in men has increased near three-fold in three decades in the United States [5].

Sexual behavior is a primary risk factor associated with anogenital tract among both men and women. A recent study demonstrated that persistence of high-risk HPVs was directly associated with the number of male anal sex partners and inversely associated with the number of female sex partners [11].

There are no clear guidelines over recommendation on the treatment and surveillance of patients with high-grade AIN [13,14]. Anal cytology as the solitary screening tool for anal cancer fails to detect anal dysplasia in a considerable number of patients [15,16]. HPV16 and HPV51 infections were associated with high-grade squamous intraepithelial lesions [12,14]. HPV16 DNA load was significantly associated with p16 (INK4a) expression, a biomarker for cancer [17,18]. The tumor cells positive for p16 are also positive for high-risk types of HPV [19].

Low sero-conversion rates following HPV infection in men may contribute to their susceptibility to recurrent infections that can progress to HPV-related cancers [20].Recurrence rates remain high regardless of the treatment delivered, and surveillance is paramount, although optimal surveillance regimens have yet to be established [16].

 

HPV-ASSOCIATED ORAL CANCER

Head and neck cancers represent a unique challenge to clinicians because of their invasive, metastatic and highly recurrent nature [21]. Investigation of the prevalence of oral HPVs in the United States showed that among men and women aged 14 to 69 years the overall prevalence of oral HPVs was 6.9% [8,22]. HPV-positive oral cancer more commonly affects the oropharynx, specifically tonsils and base of tongue [21]. More than 90% of oropharyngeal cancers are associated with oncogenic type HPV16 infection [21]. Oral HPV infections are notably more frequent in men than in women, and the incidence of HPV-positive oropharyngeal squamous cell carcinomas [HPVOSCC] has increased, predominantly among middle-aged adult men [3,24]. Significantly higher detectable HPV antibodies are found among women compared to men [20]. This may explain the differences in age-specific HPV prevalence and incidence patterns observed by gender [23]. The prevention of high risk HPV infection may result in a 4.7% reduction in the incidence rate of head and neck cancer in the United States [24].

The sharp rise in the incidence of HPV-OSCC in the United States has been attributed partially to changes in sexual norms over the past five decades, with a younger age at sexual debut and higher numbers of sexual partners per individual [17]. HPV-OSCC is associated with oral sexual behaviors [24,25]. Oral HPV was uncommon among sexually inexperienced individuals and increased significantly with the number of sexual partners [26,27]. A population-based cross-sectional study in rural China showed that the risk of oral HPV infection was significantly higher in the men with genital infection than the men uninfected [28]. This finding indicates that oral to oral and sexual transmission is the important route of oral HPV transmission. Additionally, increasing ultraviolet light exposure is also found significantly correlated to pharyngeal cancer in white males [29].Although oral HPV incidence increased in both sexes, it was more than two times higher in men than in women [25].

The host immunity has been known to play an important role in the persistence of HPV infection. A recent study identified that several innate and adaptive immunity factors, including the cyclic guanosine monophosphate-adenosine monophosphate synthase (Cgas), and an adapter protein STING, form a critical viral sensing mechanism that detects intracellular DNA and initiate antiviral response [30]. For cancer development, expression of p16 (INK4a) has been identified as one of changes in the samples [31]. A recent study showed a combination of HPV DNA and p16 (INK4a) detection is a more accurate and reliable way for active HPV infection in the head and neck squamous cell carcinoma when compared with either one of the factors alone [32]. Several Toll-like receptors (TLR 4, 5 and 9) are also de-regulated during the progression of HPV-associated neoplasia [33,34].

SUMMARY

Sexual behavior changes in the general population contribute to the epidemic HPV infection at the oral and anal sites. The incidence of anal squamous cell carcinoma is predominant in women while the incidence of oral squamous cell carcinoma is more than two times higher in men. Most studies in human populations are retrospective, and the caustic effect could not be established. Our recently established oral and anal papillomavirus mouse model will help us to explore the mechanisms of HPV-associated anal and oral cancer development [35-38].

The incidence of HPV-associated anal and oral cancers is increasing in high-risk populations including MSM, HIV-positive and immunocompromised individuals. A routine detection of the anal canal and oral sites are highly recommended in each clinic visit of HIV-infected men independently of their sexual behavior [23]. Despite discrepancies in the reported studies, several biomarkers (p16(INK4a), TLRs, etc.) together with viral DNA detection are useful predictors of HPV-associated oral and cancer development.

ACKNOWLEDGMENT

Research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R21AI121822. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

1. Nyitray AG, Iannacone MR. The epidemiology of human papillomaviruses. Curr Probl Dermatol. 2014; 45: 75-91.

2. Burchell AN, Coutlee F, Tellier PP, Hanley J, Franco EL. Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis. 2011; 204: 1723-1729.

3. Chung CH, Bagheri A, D’souza G. Epidemiology of oral human papillomavirus infection. Oral Oncol. 2014; 50: 364-369.

4. Sichero L, Nyitray AG, Nunes EM, Nepal B, Ferreira S, Sobrinho JS, et al. Diversity of human papillomavirus in the anal canal of men: the HIM Study. Clin Microbiol Infect. 2015; 21: 502-509.

5. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015; 6: 849-855. 

6. Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015; 136: 2752-2760.

7. Benevolo M, Dona MG, Ravenda PS, Chiocca S. Anal human papillomavirus infection: prevalence, diagnosis and treatment of related lesions. Expert Rev Anti Infect Ther. 2016; 14: 465-477.

8. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clinic Proceed. 2016; 91: 386-396.

9. Moscicki AB, Darragh TM, Berry-Lawhorn JM, Roberts JM, Khan MJ, Boardman LA, et al. Screening for Anal Cancer in Women. J Low Genit Tract Dis. 2015; 19: 27-42.

10. Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health. 2010; 46: 12-19.

11. Kofoed K, Sand C, Forslund O, Madsen K. Prevalence of human papillomavirus in anal and oral sites among patients with genital warts. Acta Derm Venereol. 2014; 94: 207-211.

12. Bernardi MP, Ngan SY, Michael M, Lynch AC, Heriot AG, Ramsay RG, et al. Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. Lancet Oncol. 2015; 16: 611-621.

13. Alam NN, White DA, Narang SK, Daniels IR, Smart NJ. Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II/III). Colorectal Dis. 2016; 18: 135-146.

14. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Ning L, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis. 2008; 197: 957-966.

15. Dietrich A, Hermans C, Heppt MV, Ruzicka T, Schauber J, Reinholz M. Human papillomavirus status, anal cytology and histopathological outcome in HIV-positive patients. J Euu Acad Dermatol Venereol. 2015; 29: 2011-2018.

16. Long KC, Menon R, Bastawrous A, Billingham R. Screening, Surveillance, and Treatment of Anal Intraepithelial Neoplasia. Clin Colon Rectal Surg. 2016; 29: 57-64.

17. Rodel F, Wieland U, Fraunholz I, Kitz J, Rave-Frank M, Wolff HA, et al. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer. 2015; 136: 278-288.

18. Koerber SA, Schoneweg C, Slynko A, Krug D, Haefner MF, Herfarth K, et al. Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer. Radiother Oncol. 2014; 113: 331-336.

19. Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin HR, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015; 136: 98-107.

20. Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, et al. Seroconversion Following Anal and Genital HPV Infection in Men. Papillomavirus Res. 2015; 1: 109-115.

21. Laborde RR, Novakova V, Olsen KD, Kasperbauer JL, Moore EJ, Smith DI. Expression profiles of viral responsive genes in oral and oropharyngeal cancers. Eur J Cancer. 2010; 46: 1153-1158.

22. Gillison ML, Castellsague X, Chaturvedi A, Goodman MT, Snijders P, Tommasino M, et al. Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer. 2014; 134: 497-507.

23. Kreimer AR, Pierce Campbell CM, Lin HY, Fulp W, Papenfuss MR, Abrahamsen M, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013; 382: 877-887.

24. D’Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PloS One. 2014; 9: 86023.

25. Kahn JA, Rudy BJ, Xu J, Secord EA, Kapogiannis BG, Thornton S, et al. Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth. Sex Transm Dis. 2015; 42: 246-252.

26. D’souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, et al. Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. J Clin Oncol. 2014; 32: 2408-2415.

27. Chaturvedi AK, Graubard BI, Broutian T, Pickard RK, Tong ZY, Xiao W, et al. NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men. Cancer Res. 2015; 75: 2468-2477.

28. Liu F, Hang D, Deng Q, Liu M, Xi L, He Z, et al. Concurrence of oral and genital human papillomavirus infection in healthy men: a population-based cross-sectional study in rural China. Sci Rep. 2015; 5: 15637.

29. Godar DE, Tang R, Merrill SJ. Pharyngeal and cervical cancer incidences significantly correlate with personal UV doses among whites in the United States. Anticancer Res. 2014; 34: 4993-4999.

30. Lau L, Gray EE, Brunette RL, Stetson DB. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science. 2015; 350: 568-571.

31. Burd EM. Human Papillomavirus Laboratory Testing: the Changing Paradigm. Clin Microbiol Rev. 2016; 29: 291-319.

32. Deng Z, Hasegawa M, Aoki K, Matayoshi S, Kiyuna A, Yamashita Y, et al. A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma. Int J Oncol. 2014; 45: 67-76.

33. Makinen LK, Atula T, Hayry V, Jouhi L, Datta N, Lehtonen S, et al. Predictive role of Toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. Oral Oncol. 2015; 51: 96-102.

34. Ilmarinen T, Hagstrom J, Haglund C, Auvinen E, Leivo I, Pitkaranta A, et al. Low expression of nuclear Toll-like receptor 4 in laryngeal papillomas transforming into squamous cell carcinoma. Otolaryngol Head Neck Surg. 2014; 151: 785-790.

35. Hu J, Budgeon LR, Cladel NM, Balogh K, Myers R, Cooper T, et al. Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model. J Gen Virol. 2015; 96: 3554-3565.

36. Cladel NM, Budgeon LR, Balogh KK, Cooper TK, Hu J, Christensen ND. A novel pre-clinical murine model to study the life cycle and progression of cervical and anal papillomavirus infections. PloS One. 2015;10: 120128.

37. Cladel NM, Budgeon LR, Balogh KK, Cooper TK, Hu J, Christensen ND. Mouse papillomavirus MmuPV1 infects oral mucosa and preferentially targets the base of the tongue. Virology. 2015; 488: 73-80.

38. Doorbar J. Model systems of human papillomavirus-associated disease. J Pathol. 2016; 238: 166-179.

Hu J, Peng X (2016) Gender Bias in Human Papillomavirus-Associated Anal and Oral Cancers. Clin Res Infect Dis 3(1): 1025.

Received : 16 May 2016
Accepted : 20 Jun 2016
Published : 24 Jun 2016
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X